Biotech Stock Mailbag: Labopharm
It's too early to tell if Celldex is the next Dendreon, but interim data from an ongoing, phase II study of CDX-110 in newly diagnosed GBM patients will be presented on Saturday, June 5 at the American Society of Clinical Oncology's annual meeting. This study, known as ACT-III, treats GBM patients with CDX-110 in combination with radiation and the chemotherapy drug temozolomide.
Looking at the Celldex chart, it appears the stock has already started to move in anticipation of the ASCO meeting. The ACT-III data are a key catalyst for the stock moving forward, so they're something for investors to focus on.
ASCO will post online research abstracts for the annual meeting on May 20 at 6 p.m. EDT. I don't know how much of the ACT-III data, if any, will be contained in the abstract.
I'm still putting my ASCO stock list together. Celldex is on there, so is Arqule (ARQL). Others in contention are Pharmacyclics (PCYC), Celgene (CELG), Sunesis Pharmaceuticals (SNSS) and Bristol-Myers Squibb (BMY). This isn't an exhaustive list. Let me know your favorite ASCO stock.
Speaking of Cell Therapeutics, I was pleasantly surprised to read so many supportive emails in response to my column suggesting that CEO Jim Bianco should resign for the good of shareholders. I'm still waiting for him to take my advice. George P. writes, "The Bianco piece is the best article that you have ever written. It should get a Pulitzer." Phil O. agreed. "Well done, Adam. Never owned the stock but appreciate the call to an incompetent CEO. We need more of this." Harry asks, "Out of curiosity, what is your beef with Cell Therapeutics if you don't own or short this stock? ... It seems you want to slime the guy with as much punch and venom as possible. Without reading the garbage on the message boards, let's hear it from you -- what's your beef?" I'm trying to prevent biotech investors from throwing their money away in a bad stock. Emails like this one from Gerald P. are the reason I write about Cell Therapeutics. "Great report, Adam. I watched my father lose most of his savings on this stock because a broker told him to buy in 2006 and buy hard. I have watched it over the years and it is frustrating. I hope your article saves some people some of their hard-earned money." Me too, Gerald. And thanks for your email. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
More on Biotech
|14 Biotech Stocks Facing FDA Approval
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV